Contents:
Subcutaneous Levetiracetam
Scope of the guideline
This guidance has been produced to support the use of subcutaneous levetiracetam in palliative care patients who require treatment for seizure control but are unable to take levetiracetam orally and when IV access is not an appropriate intervention.
General information
This guidance has been developed to establish a degree of consensus and uniformity in clinical practice that is likely to be beneficial to patient care despite a low quality evidence base.
Disclaimer
These Guidelines are intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.
Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.
Whilst SPAGG takes every care to compile accurate information , we cannot guarantee its correctness and completeness, and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.